Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Monday, April 30, 2012

Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity

The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumour activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.

Over years or decades chronic hepatitis B or C infection – as well as heavy alcohol consumption, hereditary liver diseases and other causes – can lead to advanced liver damage including cirrhosis and hepatocellular carcinoma (HCC), a type of liver cancer.

Read more....

No comments:

Post a Comment